(Updated - February 24, 2016 9:46 AM EST)

Fresenius Medical Care (NYSE: FMS) reported Q4 EPS of $0.52, versus the analyst estimate of $0.58. Revenue for the quarter came in at $4.35 million versus the consensus estimate of $4.41 million.

Adjusted EPS was reported as $1.04 prior, which didn't take into account an ADS ratio adjustment.

Outlook 2016

Based on the projection Fresenius Medical Care provided for 2016, the company is guiding for revenue to grow 7-10% at constant currency excluding acquisitions in 2015 and 2016. Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA is expected to increase by 15-20% in 2016 excluding acquisitions in 2015 and 2016, based on net income for 2015 of $ 1,057 million (net income excluding settlement costs for an agreement in principle for the GranuFlo®/NaturaLyre® case of -$37 million and +$9 million acquisitions).

The company expects to spend capital expenditures of $1.0 - $1.1 billion and around $750 million on acquisitions. The debt/EBITDA ratio is expected to be below 3.0 by the end of 2016.

For earnings history and earnings-related data on Fresenius Medical Care (FMS) click here.

Earnings Guidance

Form 6-K Fresenius Medical Care For: Feb 24February 24, 2016 6:29 AM